Sharon Peng M.D.

Recommended Articles

• Living with Lymphoma Day by Day

  A majority of individuals diagnosed with lymphoma find that they have to make a great deal of adjustments to their lives. There are several physical, emotional, social, and everyday obstacles from diagnosis to remission.Living with lymphoma can be different for every individual, which is why it is...

• How is Multiple Myeloma Diagnosed?

  Various tests are conducted for the diagnosis of multiple myeloma since one result of a laboratory test cannot diagnose it alone. A number of factors like the history, complete body check-up, diagnostic test reports and symptoms of the patient are taken into consideration to get a proper diagnosis...

• New Study Discovers How Lymphoma Affects Survivors’ Ability to Work

  Young adults in many countries pride themselves on their work. They have worked hard to get to where they are and there is a huge sense of accomplishment in joining the adult world and being able to provide for themselves and their new families if applicable. When cancer comes along, their ability...

• Make-A-Wish Makes a Movie Star

  Through their fundraising, on average in the United States and its territories, Make-A-Wish is able to grant the wish of a child every 34 minutes.How was it started?The Make-A-Wish Foundation started with the wish of one 7-year-old boy’s wish in 1980. Chris Grecius, who had leukemia, wanted to be...

• Lymphoma: The Importance of a Support System & Communication

  Regardless of what’s being said, communication is something that many people struggle with in their personal relationships. Communication requires self-awareness, listening skills, and the ability to empathize and convey thoughts and feelings accurately. When people are diagnosed with chronic...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...